
Alnylam-discovered cemdisiran, an siRNA silencing complement C5, is the first RNAi therapy approved for AChR-positive generalized myasthenia gravis.
Advancements in isothermal amplification technologies are fueling new diagnostic and clinical approaches for pathogen detection and cancer research.







